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Abstract
The apolipoprotein E ε4 allele contributes to the genetic susceptibility underlying a large
proportion (~40–60%) of typical, sporadic Alzheimer disease. Apolipoprotein E deficient mice
made transgenic for human apolipoprotein E ε4 accumulate excess cerebral amyloid when
compared to similarly prepared mice expressing human apolipoprotein E ε3. Therefore, it is
important to search for relevant interactions(s) between apolipoprotein E ε4 and Aβ in order to
clarify the biological role for apolipoprotein E ε4 in Alzheimer disease. Using a thioflavine T (ThT)based assay, we have investigated the effects of native human apolipoprotein E isoforms on the
kinetics of Aβ fibrillogenesis. No obvious profibrillogenic activity was detected in Aβ1-40-based
assays of any native apolipoprotein E isoform. However, when ThT assays were repeated using Aβ142, modest, but statistically significant, profibrillogenic activity was detected in both apolipoprotein
E ε3- and apolipoprotein E ε4-containing media and was similar in magnitude for the two isoforms.
These data demonstrate that native apolipoprotein E possesses "pathological chaperone"-type
activity for Aβ: in other words, the data indicate that a chaperone-like misfolding reaction can occur
between native apolipoprotein E and Aβ. However, the equipotent activities of the apolipoprotein
E ε3 and ε4 isoforms suggests the possibility that either extended co-incubation of apolipoprotein
E and Aβ, or, perhaps, the inclusion in the reaction of other fibrillogenesis-modulation co-factors
(such as metal ions, or inflammatory mediators such as reactive oxygen species, α2-macroglobulin,
apolipoprotein J, etc.) may be required for modeling in vitro the apolipoprotein E-isoform-specificregulation of extracellular Aβ accumulation that occurs in vivo. Alternatively, other events, such as
differential apolipoprotein E-isoform-mediated clearance of Aβ or of apolipoprotein E/Aβ
complexes may underlie apolipoprotein E-isoform-dependent Aβ accumulation.

Background
Genetic-neuropathological correlation indicates that the
apolipoprotein E type ε4 isoform specifies increased cere-

bral [1,2] and cerebrovascular [3] accumulation of amyloid β-protein (Aβ). In addition, the apolipoprotein E ε2
isoform can apparently prevent the expression of clinical
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Alzheimer-type dementia which is otherwise typically
associated with amyloidogenic mutations in the amyloidβ protein precursor [4]. Since the apolipoprotein E ε4
allele contributes to the genetic susceptibility underlying
a large proportion (~40–60%) of typical, sporadic Alzheimer disease, it is important to search for relevant interactions(s) between apolipoprotein E ε4 and Aβ in order to
clarify the biological role for apolipoprotein E ε4 in Alzheimer disease. Currently proposed mechanisms include
differential activities of apolipoprotein E isoforms in
modulating Aβ fibrillogenesis [5-7] and/or Aβ clearance
[8,9]. Many studies of apolipoprotein E modulation of Aβ
fibrillogenesis have utilized denatured apolipoprotein E,
purified from the serum of human apolipoprotein E
homozgotes following extraction in organic solvents [10].
While providing a convenient source of pure apolipoprotein E protein, this preparation does not represent native
apolipoprotein E as it exists in vivo. Using a thioflavine T
(ThT)-based assay [11] we have investigated the effects of
native human apolipoprotein E isoforms on the kinetics
of Aβ fibrillogenesis.

Methods
Synthetic Aβ1-40 or Aβ1-42 (Keck Foundation Protein Facility, Yale University, New Haven CT) was freshly prepared
for each assay at a concentration of 16 mg/ml in distilled,
deionized water and diluted with phosphate-buffered
saline (PBS) to generate a 5 mg/ml working solution. The
"aggregation step" consisted of a reaction mixture containing 8 µl Aβ peptide (1 mg/ml final conc) and 32 µl of
either apolipoprotein E ε3- or ε4-containing conditioned
medium or control conditioned medium from SV40
empty vector-transfected cells.
For the investigation of native apolipoprotein E preparations, apolipoprotein E isoforms were generated in the
conditioned medium of stably-transfected SV40-apolipoprotein E ε3-, or SV40-apolipoprotein E ε4-, expressing
Chinese hamster ovary (CHO) cells (CHO cells lack
detectable endogenous apolipoprotein E; data not
shown). All conditioned media were prepared using Dulbecco's minimal essential medium supplemented with
0.2% (wt/vol) bovine serum albumin only (no fetal
bovine serum). Apolipoprotein E isoform levels were
determined by quantitative immunoblotting of conditioned medium and apolipoprotein E-containing serum
standards, the latter having been kindly provided by Dr.
Petar Alaupovic of the Oklahoma Medical Research Foundation (Oklahoma City OK). Conditioned medium apolipoprotein E concentrations were then standardized using
control medium conditioned by SV40 empty vector-transfected cells as diluent, yielding a final concentration of
apolipoprotein E of 14 µg/ml, within the range of that
reported in human cerebrospinal fluid. Since the final
concentration of Aβ peptide was 1 mg/ml, the Aβ/apoli-
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poprotein E stoichiometry (molar ratio) was ~500:1, suggesting models for the Aβ/apolipoprotein E interaction
based either on a "catalytic" "pathological chaperoning"
model of apolipoprotein E action on Aβ, or with a "seeding" model of Aβ folding. Detailed biochemical characterization of this native apolipoprotein E preparation has
been reported [9].
The "aggregation step" fibrillogenesis reaction [11] was
incubated at 37°C until the time of the ThT fluorescence
measurement, which was performed from 1 to 7 days
later. For the "measurement step" [11], 960 µ1 of 10 µM
ThT (Nakarai Chemicals, Kyoto, Japan) in 50 mM phosphate buffer (pH 6.0) was added to the "aggregation step"
reaction mixture. Within 30 minutes after addition of
ThT, fluorescence was measured with a Millipore
Cytofluor (Bedford MA) in each of five successive 200 µl
aliquots of the reaction mixture, using an excitation filter
of 450 nm and an emission filter of 482 nm, and a temperature of 25°C.
In order to standardize the ThT assay in our Laboratory,
we performed studies of Aβ fibrillogenesis following 1–7
day incubations of Aβ1-40, either in physiological phosphate buffer alone or in the presence of metal ions (Zn2+,
Fe2+, or A13+; 1 mM final conc [12]. ThT fluorescence and
ultrastructural features were measured daily (not shown).
Profibrillogenic activities of the metal ions tested were in
agreement with a published report [12] (e.g., Al3+stimulated ThT fluorescence of Aβ1-40 by 3.6 ± 1.1- to 5.7 ± 1.4fold; p < 0.01), indicating that our Aβ preparations were
capable of metal ion-induced fibrillogenesis. Metals were
not present during assessment of profibrillogenic effects
of apolipoprotein E isoforms.

Results and discussion
No obvious profibrillogenic activity was detected in Aβ140-based assays of any native apolipoprotein E isoform
(Table 1). However, when ThT assays were repeated using
Aβ1-42, modest, but statistically significant, profibrillogenic activity was detected in both apolipoprotein E ε3and apolipoprotein E ε4-containing media and was similar in magnitude for the two isoforms (Table 1). The
observation of a profibrillogenic effect of apolipoprotein
E specifically for Aβ1-42 has been noted [5] and is of particular interest in light of biophysical and molecular neuropathological evidence suggesting that "long" Aβ
peptides ending at positions N-42 or N-43 are apparently
crucial for the initiation ("seeding") of Aβ deposition
[13].
These data demonstrate that native apolipoprotein E possesses "pathological chaperone"-type activity for Aβ: in
other words, the data indicate that a chaperone-like misfolding reaction can occur between native apolipoprotein
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Table 1: Effects of native apolipoprotein E isoforms on fibrillogenesis of Aβ1-40 and Aβ1-42. Fold-effects represent means ± SEM of the
quotients of ThT fluorescence values obtained for each Aβ peptide in the presence of apolipoprotein E-isoform-containing conditioned
medium divided by ThT values obtained in the presence of conditioned medium lacking apolipoprotein E, derived from empty vectortransfected cells (n = 5–6).

1 day co-incubation
7 day co-incubation

4 day co-incubation
7 day co-incubation

CHO apolipoprotein E ε3
CHO apolipoprotein E ε4
CHO apolipoprotein E ε3
CHO apolipoprotein E ε4
CHO apolipoprotein E ε3
CHO apolipoprotein E ε4
CHO apolipoprotein E ε3
CHO apolipoprotein E ε4

Aβ1-40
1.0 ± 0.l-fold
1.0 ± 0.l-fold
1.0 ± 0.l-fold
1.2 ± 0.l-fold
Aβ1-42
1.7 ± 0.27-fold
1.6 ± 0.18-fold
1.7 ± 0.22-fold
1.8 ± 0.19-fold

E and Aβ, at least at the concentrations and proportions
evaluated herein. However, the equipotent activities of
the apolipoprotein E ε3 and ε4 isoforms suggests the possibility that either extended co-incubation of apolipoprotein E and Aβ, or, perhaps, the inclusion in the reaction of
other fibrillogenesis-modulation co-factors (such as metal
ions, or inflammatory mediators such as reactive oxygen
species, α1-antichymotrypsin, heparin sulfate-protcoglycan, non-Aβ component, apolipoprotein J, complement,
etc.) may be required for modeling in vitro the apolipoprotein E-isoform-specific-regulation of extracellular Aβ
accumulation that occurs in vivo.
Alternatively, other events, such as differential apolipoprotein E-isoform-mediated clearance of Aβ or of apolipoprotein E/Aβ complexes [8,9,14] may contribute to
apolipoprotein E-isoform-dependent Aβ accumulation.
Differential anti-inflammatory activity might also play a
role. Further investigation will be required in order to elucidate the precise mechanism(s) which specify how apolipoprotein E ε4 promotes Aβ accumulation in human
brain and cerebral vessels in vivo.
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